LINC00423: A Drug Target / Disease Biomarker (G100874167)

Target Name: LINC00423

NCBI ID: G100874167

LINC00423

Other Name(s): Long intergenic non-protein coding RNA 423 | long intergenic non-protein coding RNA 423

LINC00423: A Drug Target / Disease Biomarker

LINC00423 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is a key regulator of cell adhesion and has been shown to play a role in a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

LINC00423 is a small non-coding RNA molecule that is approximately 200 amino acids long. It is produced by RNA polymerase II and is expressed in many different tissues and cells in the body. LINC00423 is typically expressed in the brain, heart, and kidneys, but it is also expressed in other organs and tissues, including the liver, pancreas, and blood cells.

One of the key functions of LINC00423 is as a regulator of cell adhesion. Adhesion is the process by which cells stick together to form tissues and organs. LINC00423 plays a key role in this process by regulating the interactions between cells and the formation of tight junctions, which are specialized barriers that help to maintain the integrity of tissues.

In addition to its role in cell adhesion, LINC00423 has also been shown to play a role in a variety of diseases. For example, LINC00423 has been shown to be downregulated in a variety of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. This suggests that LINC00423 may be a potential drug target for these diseases.

In addition to its potential as a drug target, LINC00423 has also been shown to be a potential biomarker for a variety of diseases. For example, LINC00423 has been shown to be downregulated in a variety of cancer types, including breast, lung, and ovarian cancer. This suggests that LINC00423 may be a potential biomarker for these diseases.

Another potential use for LINC00423 is as a target for drug development. By using techniques such as RNA interference and gene editing, researchers have been able to manipulate the expression of LINC00423 and study its function. This has led to the identification of potential drug candidates that can be used to treat a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Overall, LINC00423 is a fascinating molecule that has a wide range of potential applications in medicine. Its role as a regulator of cell adhesion and its potential as a drug target and biomarker make it an attractive target for research and development. Further studies are needed to fully understand the function of LINC00423 and its potential as a therapeutic agent.

Protein Name: Long Intergenic Non-protein Coding RNA 423

The "LINC00423 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC00423 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets